The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
There are currently 26 open trials
Belantamab mafodotin plus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-8)
Belantamab Mafodotin (GSK2857916)
This trial is investigating how the safety and effectiveness of belantamab mafodotin (Blenrep), pomalidomide (Imnovid) and dexamethasone (BPd) compares to pomalidomide, bortezomib (Velcade) and dexamethasone (PVd) for the treatment of relapsed and/or refractory myeloma.
Derriford Hospital, Plymouth
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have had at least one previous treatment, including lenalidomide (Revlimid).
Patients will be randomised to receive either BPd (group A) or PVd (group B).
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
Patients will be followed up for up to 7 years.
(for Medical Professionals):
A randomised, open-label, Phase III trial evaluating the safety and efficacy of belantamab mafodotin, pomalidomide and dexamethasone (BPd) compared to pomalidomide, bortezomib and dexamethasone (PVd) in relapsed and/or refractory myeloma. For more information, click here.
Healthcare professionals may be able to request access to belantamab mafodotin through an expanded access programme for multiply relapsed and/or refractory patients who do not meet the inclusion criteria for this trial.